Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347037 | 0.86 | SRC (0.51) | SRCALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL9037054 | 0.85 | CDK4 (0.36) | SRCALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL9037056 | 0.85 | CDK4 (0.36) | SRCALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL146679 | 0.84 | SRC (0.49) | SRCALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL7951806 | 0.84 | FDPS (0.41) | ALDH1A1MAPTHPGDMAPK1MEN1 | |
| SCHEMBL9672501 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPTHPGDMAPK1MEN1 | |
| SCHEMBL5989261 | 0.83 | FDPS (0.34) | SRCALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL2709918 | 0.83 | FDPS (0.47) | ALDH1A1MAPTHPGDMAPK1MEN1 | |
| SCHEMBL9672626 | 0.80 | EGFR (0.33) | SRCALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL7962228 | 0.80 | FDPS (0.45) | ALDH1A1MAPTHPGDMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0748317-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-12-18 | — | — | EP | disclosed |
| WO-1996020936-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-07-11 | — | — | WO | disclosed |
| EP-0324431-B1 | NEW INDOLYLPIPERIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | disclosed |
| US-5017703-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| US-4935432-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0324431-A1 | New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | SRC 40/4885ALDH1A1 1336/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.